Baseline demographics and clinical characteristics of the CT-P13 cohort and the subgroup of switch patients who withdrew from treatment during ≈1 year of follow-up stratified by diagnosis. Reasons for CT-P13 withdrawal are also shown
| Patients switched from INX to CT-P13 | RA* | PsA | AxSpA† | Total |
| Number of patients, n | 403 | 120 | 279 | 802 |
| Women, n (%) | 281 (70) | 58 (48) | 73 (26) | 412 (51) |
| Age, years | 63 (51–71) | 52 (44–61) | 47 (39–55) | 55 (44–66) |
| Number of comorbidities ≥1, n (%)‡ | 99 (25) | 28 (23) | 48 (17) | 175 (22) |
| Biological treatment number, INX | 1 (1–1) | 1 (1–2) | 1 (1–2) | 1 (1–1) |
| Concomitant methotrexate, n (%) | 330 (82) | 84 (69) | 89 (32) | 501 (62) |
| Methotrexate dose, mg/week§ | 15 (10–20) | 15 (10–20) | 10 (10–15) | 15 (10–20) |
| Concomitant oral prednisolone, n (%) | 25 (6) | 5 (4) | 6 (2) | 36 (4) |
| On disease remission, n (%)¶ | 191/309 (62) | 55/92 (60) | 42/199 (21) | 288/600 (48) |
| Start of INX, year, n | ||||
| 2000–2004 | 76 (19) | 11 (9) | 36 (13) | 123 (15) |
| 2005–2009 | 203 (50) | 58 (48) | 133 (48) | 394 (49) |
| 2010–2015 | 124 (31) | 51 (43) | 110 (39) | 285 (36) |
| CT-P13 dose, mg/kg | 3.4 (3.0–4.5) | 4.6 (3.1–5.1) | 4.8 (3.7–5.1) | 4.0 (3.1–5.0) |
| CT-P13 dose interval, weeks | 8 (7–8) | 7 (6–8) | 8 (6–8) | 8 (6–8) |
| Prior INX treatment duration, years | 7.3 (4.9–9.8) | 6.3 (3.1–8.5) | 6.5 (3.9–9.3) | 6.8 (4.3–9.5) |
| Prior INX treatment duration, years, mean (SD) | 7.3 (3.6) | 6.2 (3.4) | 6.6 (3.5) | 6.9 (3.6) |
| Subgroup of patients withdrawn from CT-P13 within ≈1 year of follow-up | RA* | PsA | AxSpA† | Total‡ |
| Number of patients, n | 76 | 16 | 40 | 132 |
| Women, n | 56 | 11 | 17 | 84 |
| Baseline CT-P13 dose, mg/kg | 3.6 (3.0–4.6) | 4.8 (3.0–5.5) | 5.0 (4.6–5.5) | 4.4 (3.1–5.2) |
| Concomitant methotrexate, n | 52 | 12 | 10 | 74 |
| Prior INX treatment duration, years | 6.4 (3.5–9.8) | 5.7 (2.6–9.6) | 4.8 (1.8–6.6) | 5.9 (2.9–9.2) |
| Number of comorbidities ≥1, n | 26 | 4 | 5 | 35 |
| Reasons for CT-P13 withdrawal, n=132 | ||||
| Lack of effect: 71 patients; adverse events: 37; remission: 5; cancer: 5; death: 2; several reasons: 3; other reasons (eg, pregnancy, surgery): 8; unknown: 1. | ||||
Numbers are medians (interquartile ranges) unless otherwise stated.
*RA including other types of peripheral arthritis (juvenile arthritis, reactive arthritis etc, n=39).
†AxSpA including non-radiographic axSpA (n=85) and ankylosing spondylitis (n=194).
‡The number of comorbidities was calculated according to the groups in the Charlson Comorbidity Index excluding musculoskeletal comorbidity.
§Median dose of methotrexate per week among methotrexate-treated patients.
¶The numbers of patients with available data are shown as denominator.
AxSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RA, rheumatoid arthritis.